CMS Reverses the Reimbursement for AVASTIN
November 17, 2009
Submit Comments
In a move in response to the pressure of the AAO and several other ophthalmic groups, the CMS has rescinded Code Q2024 about reimbursement for Avastin. Reimbursement now reverts back to the original pre-October 1st policy of $50 per dose.
For more, see my writeup posted this morning on my online Journal.
Comments (0)
Trackbacks
Print this post
Filed in Industry News, Macular Degeneration, Products, Retina
You might also enjoy...
- Update on Avastin vs. Lucentis: CMS Ups the Ante
- CMS Reverses Position on Avastin for AMD
- Avastin vs. Lucentis: The Origin of the Debate
- Quick Updates from ARVO 2011
- Which is More Effective – Avastin or Lucentis?
Comments
Jump down to form below to submit your own comments
